Should You Buy HIVE Digital Technologies Ltd. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, HIVE Digital Technologies Ltd. (HIVE) occupies a solid middle-ground position with a Quality of Company score of 6.2/10. At the current market price of $2.89, the investment case depends heavily on whether our 13 independent valuation models indicate a discount to fair value.
The short answer: 0 of 1 CirclFi valuation models project upside for HIVE Digital Technologies Ltd. (HIVE) at $2.89 — the model consensus leans bearish, with a Quality Score of 6.2/10 and Value-Trap risk of 43/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for HIVE Digital Technologies Ltd. (HIVE) in 2026?
What Is the Bull Case vs the Bear Case for HIVE Digital Technologies Ltd. (HIVE)?
| Bull case | Bear case — $1.91 target (-33.9%) |
|---|---|
| No active model projects meaningful upside for HIVE at $2.89. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. | According to the CirclFi Value Trap algorithm, the stock shows moderate caution signals, meaning investors should verify that apparent undervaluation isn't masking declining business quality. |
| According to the CirclFi Deep Alpha Valuation Engine, the FTNN Topology model sees the stock as overvalued with a fair value of $1.91 (-33.9%), suggesting that the market price embeds overly optimistic growth assumptions. | |
| Industry headwind: regulatory capital requirements represents a meaningful risk for HIVE Digital Technologies Ltd. and its Capital Markets peers. |
How Does HIVE Compare to Its Capital Markets Peers?
Valuation data pages: FUFU · LCLN · PURR · NIHK · BMNR · MDBH · TAOX · TIGR · SNEX · FUTU · HOOD
Which Other Stocks Score Like HIVE on Quality?
Closest companies to HIVE’s Quality of Company score of 6.2/10, across all industries.
- LEXX — Lexaria Bioscience Corp. (QOC 6.2) · analysis
- WVVI — Willamette Valley Vineyards, Inc. (QOC 6.2) · analysis
- ZDGE — Zedge, Inc. (QOC 6.2) · analysis
- BHST — BioHarvest Sciences Inc. Common Stock (QOC 6.2) · analysis
- MAAS — Maase Inc. (QOC 6.2) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Capital Markets Screens Does HIVE Appear In?
So Is HIVE Digital Technologies Ltd. (HIVE) Worth Buying in 2026?
Our valuation engine sends a clear cautionary signal on HIVE Digital Technologies Ltd. at $2.89. 1/1 models flag overvaluation, median fair value sits at $1.91 (-33.9%), and the risk-reward profile appears unfavorable. Quality at 6.2/10 adds to the concern. This is a stock where patience — or avoidance — may be the optimal strategy.
These are quantitative model outputs, not investment recommendations. HIVE Digital Technologies Ltd.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About HIVE Stock?
Should I buy HIVE stock right now?
Based on CirclFi's multi-model analysis, 0 of 1 models see upside for HIVE at $2.89. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in HIVE Digital Technologies Ltd.?
Key risks include: an elevated Value Trap score of 43/100, suggesting apparent undervaluation may mask deteriorating fundamentals; limited model coverage (1/13 active), reducing analytical confidence; general market and sector-specific risks affecting Capital Markets companies. Always diversify and consult a financial advisor.
How does HIVE compare to its competitors?
Among Capital Markets peers, HIVE holds a Quality Score of 6.2/10. Comparable companies include FUFU (QOC 6.2), LCLN (QOC 6.1), PURR (QOC 6.2). The relative ranking helps investors identify whether HIVE offers better fundamental quality than alternatives in the same sector.
Is HIVE a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. HIVE's Quality Score of 6.2/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy HIVE at?
CirclFi does not provide target buy prices or price alerts. However, our 1 active models produce fair value estimates ranging from $1.91 to $1.91. At $2.89, the stock trades above all model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for HIVE.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad